ECS Botanics’ B2C division now accounts for more than half of the firm’s revenue in a quarter which saw it report a positive net operating cashflow of A$140,000.
Unaudited revenue for Q1 FY26 was $5.7m, up 19% on Q4 FY25 and 15% up year on year, with direct-to-consumer (B2C) revenue climbing 21% during the period to $3.2m and counting for 56% of the total.
Cash receipts increased to $5.4m, up 8% on the prior quarter and 22% up on Q1 FY25.
The firm said growth was “broad-based across all product categories, highlighting the strength of ECS’s branded portfolio and the success of its multi-channel sales strategy”.
Meanwhile, ECS reported staff and manufacturing costs were both down from the previous quarter – 17% and 22% respectively – “following a record harvest, nearing completion of capital works and an ongoing focus on cost optimisation”.
The company has $2.9m in cash and available finance.
Epsilon Healthcare
Epsilon has reported revenue of A$5.6 million for the year ended December 31, 2024, down 16% on 2023, while after-tax losses deepened by 198% to $3.25m.
Epsilon blamed extraordinary costs, reputational damage and uncertainty following the company going into voluntary administration (VA) in December 2023 for the result.
It added: “B2B client and B2C patient revenues were markedly depressed as a direct result of the uncertainty caused by the voluntary administration.”
Epsilon exited VA in June last year while a deed of company arrangement (DOCA) to revive the troubled firm was effectuated in June 2025.
Epsilon ended 2024 with cash and cash equivalents of $1.57m, up from $343,000 at the end of 2023.